Advertisement

Topics

Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis

03:54 EDT 17 Apr 2019 | Pharmaceutical Business Review

Under the three-year deal, the partnership will use insitro’s platform to create disease models for NASH and discover targets that can impact clinical progression and regression of the

The post Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis appeared first on Pharmaceutical Business review.

Original Article: Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis

NEXT ARTICLE

More From BioPortfolio on "Gilead, insitro collaborate to develop therapies for nonalcoholic steatohepatitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...